Adrian Wiestner

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia
    Georg Aue
    Hematology Branch, NHLBI, NIH Bldg 10, CRC 3 5140, 10 Center Drive, Bethesda, 20892 1202 USA Ronald P Taylor, PhD, Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA, USA E mail
    Haematologica 95:329-32. 2010
  2. doi request reprint Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
    Adrian Wiestner
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD20892 1202, USA
    Hematology Am Soc Hematol Educ Program 2012:88-96. 2012
  3. pmc Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
    Adrian Wiestner
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Blood 120:4684-91. 2012
  4. pmc Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
    Patricia Perez-Galan
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 117:542-52. 2011
  5. pmc The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group
    Qiuyan Wang
    Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS ONE 5:e15479. 2010
  6. pmc Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma
    Marc A Weniger
    Hematology Branch, NHLBI, NIH, Building 10, CRC 3 5140, 10 Center Drive, Bethesda, 20892 MD, USA
    Clin Cancer Res 17:5101-12. 2011
  7. pmc ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress
    Colby M Chapman
    Hematology Branch, NHLBI, NIH, Bld 10, CRC 3 5140, 10 Center Drive, 20892 1202 Bethesda, MD, USA
    Clin Cancer Res 18:1979-91. 2012
  8. pmc Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation
    Heba A Degheidy
    Division of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Cytometry B Clin Cytom 80:309-17. 2011
  9. pmc Methodological comparison of two anti-ZAP-70 antibodies
    Heba A Degheidy
    Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Cytometry B Clin Cytom 80:300-8. 2011
  10. pmc Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
    Adrian Wiestner
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Blood 109:4599-606. 2007

Detail Information

Publications38

  1. pmc Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia
    Georg Aue
    Hematology Branch, NHLBI, NIH Bldg 10, CRC 3 5140, 10 Center Drive, Bethesda, 20892 1202 USA Ronald P Taylor, PhD, Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA, USA E mail
    Haematologica 95:329-32. 2010
    ..Subcutaneous RTX largely preserved CD20 expression on leukemic cells but the most effective therapeutic dosing regimen needs to be established (ClinicalTrials.gov Identifier: NCT00366418)...
  2. doi request reprint Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
    Adrian Wiestner
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD20892 1202, USA
    Hematology Am Soc Hematol Educ Program 2012:88-96. 2012
    ..This review discusses the biologic basis for kinase inhibitors as targeted therapy of CLL and summarizes the exciting early clinical experience with these agents...
  3. pmc Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
    Adrian Wiestner
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Blood 120:4684-91. 2012
    ..This review discusses the biologic basis for kinase inhibitors as targeted therapy of CLL and summarizes the exciting early clinical experience with these agents...
  4. pmc Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
    Patricia Perez-Galan
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 117:542-52. 2011
    ..Expression of CD38 and IRF4 could serve as markers of bortezomib resistance in MCL. This study has been registered at http://clinicaltrials.gov as NCT00131976...
  5. pmc The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group
    Qiuyan Wang
    Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS ONE 5:e15479. 2010
    ..We recently reported that the ERAD inhibitor Eeyarestatin I (EerI) also disturbs ER homeostasis and has anti-cancer activities resembling that of Bortezomib...
  6. pmc Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma
    Marc A Weniger
    Hematology Branch, NHLBI, NIH, Building 10, CRC 3 5140, 10 Center Drive, Bethesda, 20892 MD, USA
    Clin Cancer Res 17:5101-12. 2011
    ..Up to 50% of patients with relapsed mantle cell lymphoma (MCL) respond to bortezomib. We used gene expression profiling to investigate the connection between proteasome inhibition, cellular response, and clinical efficacy...
  7. pmc ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress
    Colby M Chapman
    Hematology Branch, NHLBI, NIH, Bld 10, CRC 3 5140, 10 Center Drive, 20892 1202 Bethesda, MD, USA
    Clin Cancer Res 18:1979-91. 2012
    ..Our aim was to analyze the efficacy of ON 01910.Na against CLL cells in vitro and investigate the molecular effects of this drug on tumor biology...
  8. pmc Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation
    Heba A Degheidy
    Division of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Cytometry B Clin Cytom 80:309-17. 2011
    ..In a companion methodological study, we compared two anti-ZAP-70 clones (1E7.2 AF 488 and SBZAP PE) and four selected methods of analysis. Clinical correlations are required for validation...
  9. pmc Methodological comparison of two anti-ZAP-70 antibodies
    Heba A Degheidy
    Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Cytometry B Clin Cytom 80:300-8. 2011
    ..ZAP-70 expression is a stage independent prognostic marker in CLL. However, interlaboratory variation is large, and there is neither a consensus nor a regulatory approved methodology...
  10. pmc Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
    Adrian Wiestner
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Blood 109:4599-606. 2007
    ..We conclude that alterations of CCND1 3'UTR structure can significantly increase its oncogenic effect and worsen the clinical course of MCL patients...
  11. pmc The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia
    Yair Herishanu
    National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 117:563-74. 2011
    ..These data identify the disruption of tumor microenvironment interactions and the inhibition of BCR signaling as promising therapeutic strategies in CLL. This study is registered at http://clinicaltrials.gov as NCT00019370...
  12. pmc Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia
    Clifton C Mo
    Hematology Branch, NHLBI, NIH, Bethesda, MD, USA
    Haematologica 98:1259-63. 2013
    ..More frequent dosing of rituximab may be required to prevent autoimmune complications in at-risk patients (clinicaltrials.gov identifier:00001586). ..
  13. doi request reprint Bcl-2 level as a biomarker for 13q14 deletion in CLL
    Heba A Degheidy
    Center for Biologics Evaluation and Research, FDA, Bethesda, MD, USA
    Cytometry B Clin Cytom 84:237-47. 2013
    ..Therefore, Bcl-2 expression was examined more closely to determine whether it would predict 13q14 deletion status...
  14. pmc Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1
    Yair Herishanu
    Hematology Branch, National Heart, Blood, and Lung Institute, National Cancer Institute, National Institutes of Health, Bethesda, MD20892 1202, USA
    Leuk Lymphoma 52:1758-69. 2011
    ..Inhibition of MCL-1 is a promising strategy to reduce the anti-apoptotic effect of the microenvironment on CLL cells...
  15. pmc TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation
    Berengere Vire
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 187:4040-50. 2011
    ..In addition, FcμR deserves study as a potential pathway for the delivery of therapeutic Ab-drug conjugates into CLL cells...
  16. pmc ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells
    Qiuyan Wang
    Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 106:2200-5. 2009
    ..Our results identify a class of anticancer agents that integrate ER stress response with an epigenetic mechanism to induce cell death...
  17. ncbi request reprint Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma
    Elaine M Hurt
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Cell 5:191-9. 2004
    ..The frequent overexpression of c-maf in myeloma makes it an attractive target for therapeutic intervention...
  18. ncbi request reprint Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response
    Andreas Rosenwald
    Metabolism Branch, Center for Cancer Research, National Cancer Institute NIH, Bldg 10, Rm 4N114, Bethesda, MD 20892, USA
    Blood 104:1428-34. 2004
    ..These considerations suggest that fludarabine treatment should be given in strict accordance to the current National Cancer Institute (NCI) guidelines that have established criteria of disease activity that warrant treatment...
  19. pmc Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
    Georg Aue
    Hematology Branch, National Heart, Lung, and Blood Institute NIH, 10 Center Drive, Bethesda, MD 20892 1202, USA
    Haematologica 94:1266-73. 2009
    ..We conducted this study to investigate the mechanism of action of lenalidomide and the basis for its unique toxicities in chronic lymphocytic leukemia...
  20. doi request reprint Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia
    Prashant R Tembhare
    Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr, Bethesda, MD, 20892
    Am J Clin Pathol 140:813-8. 2013
    ..Studies suggest that levels of surface antigen expression may affect response to monoclonal antibody-based therapy...
  21. doi request reprint Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia
    Sivasubramanian Baskar
    Experimental Transplantation and Immunology Branch and Metabolism Branch, Center for Cancer Research, National Cancer Institute, and Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD 20892 1203, USA
    Clin Cancer Res 14:396-404. 2008
    ..To assess the suitability of ROR1 as a cell surface antigen for targeted therapy of B-CLL, we carried out a comprehensive analysis of ROR1 protein expression...
  22. ncbi request reprint Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
    Ruth Seggewiss
    Hematology Branch, National Heart, Lung, and Blood Institute NHLBI, the Immunology Laboratory, NIH DHHS, Bldg 10, CRC, Rm 4 5140, 10 Center Dr, MSC 1202, Bethesda, MD 20892, USA
    Blood 105:2473-9. 2005
    ....
  23. pmc A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
    George Wright
    Biometric Research Branch, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:9991-6. 2003
    ..These results demonstrate the ability of this gene expression-based predictor to classify DLBCLs into biologically and clinically distinct subgroups irrespective of the method used to measure gene expression...
  24. doi request reprint Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways
    Edgar Gil Rizzatti
    Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    Leuk Lymphoma 49:798-808. 2008
    ..We conclude that bortezomib can overcome classic mechanisms of resistance to apoptosis and that determinants of bortezomib sensitivity in MCL are due to differences in signaling or stress pathways upstream of Noxa...
  25. pmc Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies
    Jiahui Yang
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 6:e21018. 2011
    ..To further assess the suitability of ROR1 for targeted therapy of CLL and MCL, a panel of mAbs was generated and its therapeutic utility was investigated...
  26. pmc Combined normal donor and CLL: Single tube ZAP-70 analysis
    Heba A Degheidy
    Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, USA
    Cytometry B Clin Cytom 82:67-77. 2012
    ..Based on our previous studies, we have developed a combined one-tube technology with multiple internal controls to optimize ZAP-70 assessment...
  27. ncbi request reprint The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
    Andreas Rosenwald
    The Lymphoma Leukemia Molecular Profiling Project, National Cancer Institute NIH, Bethesda, MD, USA
    Cancer Cell 3:185-97. 2003
    ..We propose a quantitative model of the aberrant cell cycle regulation in MCL that provides a rationale for the design of cell cycle inhibitor therapy in this malignancy...
  28. pmc Targeting malignant B cells with an immunotoxin against ROR1
    Sivasubramanian Baskar
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    MAbs 4:349-61. 2012
    ..Our data suggest that ROR1-immunotoxins such as BT-1 could serve as targeted therapeutic agents for ROR1-expressing B cell malignancies and other cancers...
  29. ncbi request reprint Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies
    Matthias Grube
    Hematology Branch, National Heart Lung Blood Institute NIH, 9000 Rockville Pike, Building 10, Bethesda, MD 20892, USA
    Clin Cancer Res 10:1047-56. 2004
    ..To investigate potential immunotherapeutic strategies in B lymphocytic malignancies we looked for CTLs recognizing CD19 and CD20 epitopes...
  30. pmc Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia
    Georg Aue
    Hematology Branch, NHLBI, NIH, Bethesda, Maryland 20892 1202, USA
    Am J Hematol 86:835-40. 2011
    ..65, p < 0.001). These data link lenalidomide associated DVTs with TNFα upregulation and endothelial cell dysfunction and suggest that aspirin may have a role for DVT prophylaxis in these patients...
  31. pmc Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia
    Angelique Biancotto
    Center for Human Immunology, Autoimmunity and Inflammation, National Heart Lung and Blood Institute, Bethesda, MD, USA
    Mod Pathol 25:246-59. 2012
    ....
  32. pmc Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
    Patricia Perez-Galan
    Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892 1202, USA
    Blood 117:26-38. 2011
    ..Given its unique biology, relative rarity, and the difficulty in achieving long-lasting remissions with conventional approaches, patients with MCL should be encouraged to participate in clinical trials...
  33. ncbi request reprint Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines
    Ana I Robles
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute and Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 12:6547-56. 2006
    ..We aimed to establish the optimal schedule for administration of both drugs in combination and the molecular basis for their interaction...
  34. ncbi request reprint Towards molecular diagnosis and targeted therapy of lymphoid malignancies
    Adrian Wiestner
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    Semin Hematol 40:296-307. 2003
    ..The full benefit of gene expression profiling can only be realized if we incorporate this technology into prospective clinical trials...
  35. ncbi request reprint Prognostic factors for risk-adapted therapy in chronic lymphocytic leukemia - the search continues
    Yair Herishanu
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Leuk Lymphoma 48:1468-9. 2007
  36. ncbi request reprint ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile
    Adrian Wiestner
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Blood 101:4944-51. 2003
    ..We developed reverse transcriptase-polymerase chain reaction and immunohistochemical assays for ZAP-70 expression that can be applied clinically and would yield important prognostic information for patients with CLL...
  37. pmc Molecular targeted approaches in mantle cell lymphoma
    Marc A Weniger
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Hematol 48:214-26. 2011
    ..Participation in clinical trials offers patients an immediate chance to benefit from these advances and is essential to maintain the momentum of progress...
  38. ncbi request reprint Rituximab in the treatment of acquired factor VIII inhibitors
    Adrian Wiestner
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 100:3426-8. 2002
    ..Responses continue off treatment from more than 7 to more than 12 months. This report adds to the growing evidence that rituximab has efficacy in immune disorders resulting from autoantibody formation...